Abstract: The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diaposis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, it a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis.

Abstract: The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diaposis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, it a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis.

Abstract: The invention provides a process for analysis of the presence of atherosclerosis in a patient sample, and preferably identifies a form of atherosclerosis that correlates to an increased risk of the patient to develop rheumatoid arthritis (RA), connective tissue diseases, vasculitis, and/or spondyloarthritis, and/or myocardial infarction and/or apoplexy.

Abstract: Provided herein are methods for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR), and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. In addition, test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject are also provided.

Abstract: The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis.

Abstract: An electromagnet having a pole tube, and having a coil that encompasses the pole tube and is mounted so as to be displaceable along a longitudinal axis of the pole tube, a first end face of the coil or of the housing thereof bearing on a first counter-bearing disposed at a first end portion of the pole tube, and an elastic element, which is supported on a second counter-bearing and biases the coil and/or the housing thereof against the first counter-bearing, is provided between a second end face of the coil or the housing thereof and the second counter-bearing disposed at a second end portion of the pole tube.

Abstract: The present inventions relates generally to methods for diagnosing the presence or the risk of development or the therapy control of vasculitis, in particular, of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR) and Takayasu's arteritis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject.

Abstract: The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis.

Abstract: An electromagnet having a pole tube, and having a coil that encompasses the pole tube and is mounted so as to be displaceable along a longitudinal axis of the pole tube, a first end face of the coil or of the housing thereof bearing on a first counter-bearing disposed at a first end portion of the pole tube, and an elastic element, which is supported on a second counter-bearing and biases the coil and/or the housing thereof against the first counter-bearing, is provided between a second end face of the coil or the housing thereof and the second counter-bearing disposed at a second end portion of the pole tube.

Abstract: Medical use of ILT6 for modulating the immune response, as well as to pharmaceutical compositions containing ILT6. In a further aspect, the present invention relates to the medical treatment of human beings using ILT6 to modulate their immune response, for example directed against heterologous and/or autologous antigens. Furthermore, the present invention relates to the analysis using ILT6 for diagnostic purposes and to diagnostic compositions that can be employed for that analysis.

Abstract: A valve system has a valve housing, in which at least one valve element is displaceably guided. At least one magnetic field sensor is provided to detect the position of the valve element, which is acted upon by the magnetic field of at least one permanent magnet located on the movable valve element. The permanent magnet is guided relative to the magnetic field sensor such that it is non-rotatable but axially displaceable in the valve housing.

Abstract: The invention relates to a method of diagnosing Sjögren's syndrome and to a suitable kit of reagents.

Abstract: A method for the production of a means for treating or preventing systemic lupus erythematosus is disclosed. Said means comprises IgM for sub-cutaneous and/or intra-muscular application. A preferred IgM is autoantigen IgM, in particular anti-ds-DNA and anti-phospholipid IgM. A pharmaceutical combination package for treatment of SLE is also disclosed, containing the IgM antibodies, together with at least one anti-inflammatory agent, at least one immuno-suppressive agent and/or at least one cytostatic agent for simultaneous and/or serial application.

Abstract: A lifting magnet arrangement. The arrangement has a thrust direction in which a pressure spring which biases the armature into its basic position may be set. This is done by an actuating section designed to project from the magnet housing. By using this configuration it is not necessary to open the magnet housing for adjustment so that the adjusting process may be carried out with an oil-floated armature.